Program Overview
Orion Biotech is developing a bio-targeted peripheral motor-intention interface—a module within the broader brain–computer interface and prosthetic-control stack. The immediate readout target is not cortical activity alone, but arm-side motor output pathways: peripheral motor axons, neuromuscular junction regions, and downstream execution signals.
The central hypothesis is that a biological targeting layer can position sensors closer to relevant motor terminals, improving motor-unit identity, signal separation, and intent decoding beyond conventional surface EMG systems.
Technical Approach
The architecture combines a neuromuscular addressing layer, axon-proximal signal acquisition, multi-site decoding, and closed-loop calibration against actual limb movement. Upper-arm, forearm, and wrist readout levels cross-reference one another so the system learns reliability weights over time rather than trusting any single channel.
Early development emphasizes in vitro proof-of-concept, addressable biohybrid readout structures, and neural codec front-end design—building toward rehabilitation and assistive applications with rigorous validation.
Translational Outlook
Potential applications include neural rehabilitation after paralysis or amputation, advanced prosthetic control, and high-dimensional assistive robotics. The program is at research and platform stage; no clinical product claims are made.
We welcome collaborations with rehabilitation clinics, neural-engineering groups, and device partners pursuing human-centered, evidence-driven interface development.